| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
28,770,000 |
| Market
Cap: |
310.14(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.37 - $41.8 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Biomea Fusion is a biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Co.'s proprietary FUSION System discovery platform is built to advance a pipeline of novel irreversible small molecule product candidates. Co.'s lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
9,100 |
| Total Buy Value |
$0 |
$0 |
$0 |
$70,936 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
400,000 |
1,100,000 |
| Total Sell Value |
$0 |
$0 |
$13,684,945 |
$33,230,447 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
5 |
11 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Erdtmann Rainer M |
President and COO |
• • – |
2023-12-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
21,000 |
713,027 |
|
- |
|
| Erdtmann Rainer M |
President and COO |
• • – |
2023-12-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
9,000 |
10,000 |
|
- |
|
| Valle Franco |
Chief Financial Officer |
• – – |
2023-11-30 |
4 |
A |
$3.78 |
$5,087 |
D/D |
1,345 |
25,543 |
|
- |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2023-06-01 |
4 |
S |
$34.56 |
$1,728,165 |
D/D |
(50,000) |
3,500,000 |
|
66% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2023-05-31 |
4 |
S |
$33.81 |
$2,535,750 |
D/D |
(75,000) |
3,550,000 |
|
63% |
|
| Valle Franco |
Chief Financial Officer |
• – – |
2023-05-31 |
4 |
A |
$3.78 |
$16,163 |
D/D |
4,273 |
24,198 |
|
- |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2023-05-12 |
4 |
S |
$33.84 |
$846,000 |
D/D |
(25,000) |
3,625,000 |
|
59% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2023-05-09 |
4 |
S |
$34.50 |
$5,175,720 |
D/D |
(150,000) |
3,650,000 |
|
55% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2023-05-08 |
4 |
S |
$33.99 |
$3,399,310 |
D/D |
(100,000) |
3,800,000 |
|
55% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2023-04-20 |
4 |
S |
$29.12 |
$5,823,760 |
D/D |
(200,000) |
3,900,000 |
|
45% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2023-03-31 |
4 |
S |
$31.25 |
$6,250,000 |
D/D |
(200,000) |
4,100,000 |
|
40% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2023-03-31 |
4/A |
S |
$31.25 |
$6,250,000 |
D/D |
(200,000) |
4,100,000 |
|
- |
|
| Valle Franco |
Chief Financial Officer |
• – – |
2022-11-30 |
4 |
A |
$3.78 |
$9,524 |
D/D |
2,518 |
19,925 |
|
- |
|
| Hitchcock Michael J.m. |
Director |
– • – |
2022-11-14 |
4 |
B |
$7.93 |
$39,650 |
D/D |
5,000 |
5,000 |
2.39 |
285% |
|
| Valle Franco |
Chief Financial Officer |
• – – |
2022-11-11 |
4 |
B |
$7.63 |
$31,286 |
D/D |
4,100 |
17,407 |
2.74 |
95% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2022-08-16 |
4 |
S |
$13.87 |
$425,648 |
D/D |
(30,684) |
4,300,000 |
|
46% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2022-07-21 |
4 |
S |
$11.21 |
$388,516 |
D/D |
(34,658) |
4,330,684 |
|
40% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2022-06-24 |
4 |
S |
$11.76 |
$407,578 |
D/D |
(34,658) |
4,365,342 |
|
3% |
|
| Biomea Health, Llc |
10% Owner |
– – • |
2022-06-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,365,342) |
0 |
|
- |
|
| Valle Franco |
Chief Financial Officer |
• – – |
2022-05-31 |
4 |
A |
$4.67 |
$15,432 |
D/D |
3,307 |
13,307 |
|
- |
|
| Valle Franco |
Chief Financial Officer |
• – – |
2022-01-14 |
4 |
B |
$8.68 |
$86,767 |
D/D |
10,000 |
10,000 |
2.74 |
-37% |
|
| Stergiopoulos Sotirios |
Director |
– • – |
2021-09-17 |
4 |
B |
$10.96 |
$379,852 |
I/I |
34,658 |
4,400,000 |
2.1 |
-38% |
|
| A2a Pharmaceuticals, Inc. |
10% Owner |
– – • |
2021-09-17 |
4 |
B |
$10.96 |
$379,852 |
D/D |
34,658 |
4,400,000 |
2.45 |
-38% |
|
| Erdtmann Rainer M |
President & COO |
• • • |
2021-08-23 |
4 |
B |
$13.20 |
$316,872 |
I/I |
24,000 |
228,470 |
2.64 |
-36% |
|
| Butler Thomas Andrew |
CEO |
• • • |
2021-08-23 |
4 |
B |
$13.20 |
$316,872 |
I/I |
24,000 |
228,470 |
2.64 |
-36% |
|
40 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.31 (2.96%) 
